<DOC>
	<DOC>NCT00396149</DOC>
	<brief_summary>To investigate the safety and tolerability of successive single rising doses of SLIT in subjects with allergic rhinitis and to investigate the safety and tolerability of multi high dose regimens of SLIT in subjects with allergic rhinitis.</brief_summary>
	<brief_title>Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
	<criteria>written consent Symptoms of birch pollen induced allergic rhinitis for at least the last 2 years. Sensitisation to birch pollen as demonstrated with a positive SPT to birch pollen and specific IgE level (birch pollen and r Bet v1) of at least Class 2 at screening. FEV1 at least of 80% of predicted values at screening. Patient who previously received desensitization treatment to birch pollen and/or other betulaceae (e.g., hazel tree, alderâ€¦) or who plan to start desensitization treatment during this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>rBet v 1</keyword>
	<keyword>Birch pollen allergy</keyword>
	<keyword>Sublingual Immunotherapy</keyword>
</DOC>